<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03918109</url>
  </required_header>
  <id_info>
    <org_study_id>313-201901</org_study_id>
    <nct_id>NCT03918109</nct_id>
  </id_info>
  <brief_title>OTO-313 in Subjects With Subjective Tinnitus</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-313 Given as a Single Intratympanic Injection in Subjects With Subjective Tinnitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otonomy, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otonomy, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, plasma pharmacokinetics
      (PK), and exploratory efficacy of OTO-313 administered as an intratympanic injection for the
      treatment of subjective tinnitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 4, 2019</start_date>
  <completion_date type="Actual">May 29, 2020</completion_date>
  <primary_completion_date type="Actual">May 29, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled, multicenter</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Emergent Adverse Events</measure>
    <time_frame>Reported or observed during or after dosing (Day 1) up to end of study (Day 57 - 8 weeks after dosing)</time_frame>
    <description>An adverse event (AE) is any unfavorable and unintended diagnosis, symptom, sign, syndrome or disease which occurs during the study, having been absent at baseline, or, if present at baseline, appears to worsen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Audiometry</measure>
    <time_frame>After dosing (Day 1) up to end of study (Day 57 - 8 weeks after dosing)</time_frame>
    <description>Clinically significant adverse change from Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Otoscopic Examinations</measure>
    <time_frame>After dosing (Day 1) up to end of study (Day 57 - 8 weeks after dosing)</time_frame>
    <description>Clinically significant adverse change from Baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK)</measure>
    <time_frame>Specified timepoints for the first 24 hours and 1 week later</time_frame>
    <description>Concentrations of gacyclidine in plasma</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Tinnitus Functional Index</measure>
    <time_frame>At screening, baseline (Day 1), Day 15, Day 29, Day 57</time_frame>
    <description>Validated, 25-item questionnaire; index score from 0 to 100; higher scores indicate greater problem with tinnitus</description>
  </other_outcome>
  <other_outcome>
    <measure>Daily Tinnitus Annoyance</measure>
    <time_frame>Start of Lead-in (Day -14) to end of study (Day 57)</time_frame>
    <description>Numerical rating scale from 0 (Not Annoying) to 10 (Extremely Annoying) collected every day</description>
  </other_outcome>
  <other_outcome>
    <measure>Daily Tinnitus Loudness</measure>
    <time_frame>Start of Lead-in (Day -14) to end of study (Day 57)</time_frame>
    <description>Numerical rating scale from 0 (No Tinnitus) to 10 (Extremely Loud Tinnitus) collected every</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Global Impression of Change</measure>
    <time_frame>Day 8, Day 15, Day 29, Day 57</time_frame>
    <description>Change in overall tinnitus status as perceived by the subject</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Tinnitus, Subjective</condition>
  <arm_group>
    <arm_group_label>OTO-313</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTO-313</intervention_name>
    <description>single intratympanic injection of gacyclidine</description>
    <arm_group_label>OTO-313</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single intratympanic injection of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has subjective unilateral tinnitus and is consistently aware of their tinnitus
             throughout much of the waking day.

          -  Subject is able to use the electronic diary to complete their daily tinnitus ratings

          -  Subject's tinnitus is likely of cochlear origin, e.g., associated with sensorineural
             hearing loss; acute hearing loss from noise trauma, barotrauma, or traumatic cochlear
             injury (acute acoustic trauma, blast trauma, middle ear surgery, inner ear
             barotrauma); age-related hearing loss; resolved otitis media; ototoxic drug exposure.

          -  Subject is willing to comply with the protocol and attend all study visits.

        Exclusion Criteria:

          -  Subject has pulsatile tinnitus, tinnitus resulting from traumatic head or neck injury,
             or tinnitus resulting from a tumor or stroke.

          -  Subject is pregnant or lactating.

          -  Subject has other clinically significant illness, medical condition or medical history
             at Screening or Baseline (Day 1) that, in the Investigator's opinion, would likely
             reduce the safety of study participation or compliance with study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>House Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Head &amp; Neck Specialists</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado ENT and Allergy</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silverstein Institute/Ear Research Foundation</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ChicagoENT</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced ENT and Allergy</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tandem Clinical Research, LLC</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group</name>
      <address>
        <city>Berkeley Heights</city>
        <state>New Jersey</state>
        <zip>10882</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dent Neurosciences Research Center</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health, Hearing &amp; Speech Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health at ENT and Allergy Associates</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Eye Ear Nose &amp; Throat Associates</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Ear, Nose, and Throat Associates</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Worldwide Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chrysalis Clinical Research</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WVU Medicine</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 15, 2019</study_first_submitted>
  <study_first_submitted_qc>April 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2019</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tinnitus, intratympanic injection, gacyclidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

